Kuros Biosciences AG, of Zurich, Switzerland, said it sold 1.15 million new shares (excluding an overallotment option of up to 200,000 shares) to existing and new investors at a price of CHF12.50 (US$13.08) per share. In total, the company raised gross proceeds of CHF14.4 million (US$15 million) that will support the market launch of lead products Magnetos, a synthetic bone graft substitute, and Neuroseal, a dural sealant, as well as certain important activities for ongoing fibrin-PTH development programs.